NEW YORK (GenomeWeb) – Israeli cancer diagnostics developer NovellusDx has raised $10 million in a private financing round.
The round, led by life sciences holding company IntraCure and life sciences venture capital financier Pontifax, includes an option for an additional $10 million investment, the company said in a statement.
Founded in 2012, the firm has developed technology to monitor signaling pathways and identify driver mutations in different kinds of cancer, and monitor the effects of targeted therapies on those mutations.
NovellusDx, which employs 20 people in Jerusalem, will used the proceeds from the financing round to continue research and development and to build a commercial service lab.